LONDON, Aug 14 (Reuters) - Dutch biotech group Crucell is on the look-out for further acquisitions within a consolidating sector and might itself be attractive to a larger player, its chief executive said on Thursday. “We have over 160 million euros ($240 million) and we’re not consuming cash, and that gives us a good position to see what’s out there,” Ronald Brus told Reuters during a visit to London.
